What is the ongoing treatment and management plan for respiratory failure in a patient with Duchenne muscular dystrophy?

Ongoing Management of Respiratory Failure in Duchenne Muscular Dystrophy

Non-invasive ventilation (NIV) is the cornerstone of ongoing respiratory management in DMD patients with respiratory failure, combined with mechanical insufflation-exsufflator (MI-E) for airway clearance, and should be initiated when hypoxemia (saturations <95%) or hypercapnia (>45 mmHg/6 kPa) develops. 1

Core Management Strategy

Primary Ventilatory Support

• Initiate NIV immediately when any of the following occur:

  • Oxygen saturations <95%
  • CO2 levels >45 mmHg (6 kPa)
  • Respiratory rate exceeds age-appropriate early warning scores
  • Patient shows signs of tiring 1

• Progress ventilatory support systematically:

  • Start with bilevel positive airway pressure (BPAP)
  • Advance to BPAP through home mechanical ventilation devices for improved battery life
  • Add as-needed mouthpiece ventilation (MPV) for daytime support 2
  • Many patients eventually require continuous (24-hour) NIV support—79.5% in advanced stages 3

Airway Clearance Management

MI-E must be used regularly alongside NIV, particularly during respiratory infections 1. This is critical because:

• Cough peak flow is severely impaired (median 0 L/min without assistance) 3
• Lung volume recruitment (LVR) can increase CPF to 150 L/min 3
• 95.5% of patients in advanced stages require MI-E 3
• Regular physiotherapy with MI-E prevents mucus retention and reduces pneumonia risk (70.5% of patients have pneumonia history) 3

Critical Oxygen Management Principles

Avoid oxygen therapy in isolation—it is relatively contraindicated without concurrent NIV because it worsens hypercapnia in patients with diaphragmatic weakness 1.

Oxygen Administration Rules:

• Target saturations: 88-92% in adults, >92% in children 1
• Always check CO2 levels before administering oxygen
• Saturations 92-95% indicate high-risk patients requiring close monitoring even without supplemental oxygen 1
• High or increasing oxygen requirements mandate urgent NIV reassessment 1

Monitoring and Follow-Up Protocol

Regular Assessment Schedule:

• Optimize NIV parameters at each clinic visit through assessment of:

  • Mode, inspiratory time, inspiratory and expiratory pressures
  • Sleep quality via polysomnography
  • Blood gas analysis (capillary or arterial)
  • Transcutaneous CO2 monitoring 1, 2

• Monitor lung insufflation capacity using LVR, which enables evaluation even in advanced-stage patients (median insufflation volume 1040 mL achievable) 3

Escalation Pathway for NIV Failure

If NIV becomes inadequate, invasive mechanical ventilation via tracheostomy should be considered for single-organ respiratory failure, as recovery prospects are good 1.

Decision-Making for Invasive Ventilation:

• Discuss with specialist respiratory team experienced in DMD management 1
• Consider when NIV intolerance develops or continuous support exceeds 24 hours based on patient comfort 2
• Extubation must be planned and performed in specialist centers with NIV and MI-E support immediately post-extubation 1
• Tracheostomy decisions require specialist center consultation—early tracheostomy during weaning has not shown mortality benefit 1

Emergency Management Considerations

Key Pitfalls to Avoid:

• DMD patients may not display typical respiratory distress signs (labored breathing, accessory muscle use) due to generalized weakness 1
• Low threshold for critical care admission is essential 1
• Contact primary respiratory and neuromuscular teams immediately during acute deterioration 1
• Ensure individualized emergency healthcare plans are in place and accessible 1

Acute Deterioration Protocol:

• Urgent physiotherapist assessment for airway clearance 1
• Enhanced monitoring with low threshold for blood gas analysis 1
• Management in critical care or respiratory support unit due to sudden deterioration risk 1
• NIV is initial treatment choice for chest infections 1

Adjunctive Therapies

• Continue long-term corticosteroid therapy to delay respiratory decline 4
• Cardioprotective treatments (median ejection fraction 42% in advanced stages) 3
• Nutritional management to support respiratory health 4
• Infection prevention strategies given 70.5% pneumonia history rate 3

Long-Term Outcomes

With comprehensive respiratory management including NIV and MI-E, life extension of 10+ years is now routine 5. The 18.2% mortality rate in advanced-stage patients (median age 37 years) 3 demonstrates improved survival compared to historical outcomes when respiratory support was unavailable.